コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r the intestinal absorption of vitamin D(2) (ergocalciferol).
2 be revised to include even higher dosing of ergocalciferol.
3 g/day) or high-dose (400 IU/1200 mg/day plus ergocalciferol 20 000 IU/week) VitD/Ca supplementation f
4 In healthy persons with low 25(OH)D(total), ergocalciferol administration for 12 wk normalizes 25(OH
5 rform a detailed assessment of the effect of ergocalciferol administration on glucose and insulin met
6 g/ml at baseline to 39.2+/-14.9 ng/ml in the ergocalciferol arm and did not change (16.9+/-6.4 ng/ml
7 conclusion, 6 months of supplementation with ergocalciferol increased serum 25(OH)D levels in patient
8 o assess the effects of supplementation with ergocalciferol on epoetin utilization and other secondar
9 change in epoetin dose over 6 months in the ergocalciferol or placebo arms (geometric mean rate 0.98
11 riol or vitamin D/aa[analogs & derivates] or ergocalciferol or vitamin D/bl[blood]; and with accident
12 the recommended course of 400,000 IU of oral ergocalciferol over 2 months, and only five (8%) respond
13 e recommended second course of 800,000 IU of ergocalciferol over 2 months, none demonstrated correcti
14 elow 30 ng/ml, and the currently recommended ergocalciferol repletion regimen often does not fully co
15 ferol (vitamin D(2)) resulting in a yield of ergocalciferol that was equivalent to 2142.01 ug/g dry w
18 to ultra-violet radiation for conversion to ergocalciferol (vitamin D(2)) resulting in a yield of er